Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Cathomas

Showing results (81-90 of 139) with videos related to

Pageof 14
Sort By:
World Journal of Urology|March 30, 2025
Perioperative cisplatin-based chemotherapy for muscle-invasive bladder cancer: a decision analysisLuca Afferi, Beate Jahn, Amar H Kelkar, et al.
Praxis|September 20, 2018
[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]Aurelius Omlin, Martin Spahn, Jörg Beyer, et al.
European Urology Open Science|May 15, 2023
Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice ExperimentDominik Menges, Michela C Piatti, Aurelius Omlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2023
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate CancerAurelius Omlin, Richard Cathomas, Gunhild von Amsberg, et al.
JAMA Network Open|April 21, 2026
Prostate Cancer Incidence, Mortality, and Survival in SwitzerlandDominik Menges, Lea Wildisen, Thomas Scherer, et al.
Urologic Oncology|February 21, 2026
Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective studyEmily Rinderknecht, Gloria Bielstein, Richard Cathomas, et al.
Clinical Lung Cancer|December 21, 2016
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialOliver Gautschi, Sacha I Rothschild, Qiyu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2021
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or EnzalutamideJohann S de Bono, Mark T Fleming, Judy S Wang, et al.
Swiss Medical Weekly|September 8, 2021
Swiss germ-cell cancer consensus recommendationsJörg Beyer, Dominik Berthold, Peter-Karl Bode, et al.
European Urology|May 4, 2020
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 GuidelinesJ Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al.
Pageof 14

Showing results (81-90 of 139) with videos related to

Sort By:
Pageof 14
World Journal of Urology|March 30, 2025
Perioperative cisplatin-based chemotherapy for muscle-invasive bladder cancer: a decision analysisLuca Afferi, Beate Jahn, Amar H Kelkar, et al.
Praxis|September 20, 2018
[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation]Aurelius Omlin, Martin Spahn, Jörg Beyer, et al.
European Urology Open Science|May 15, 2023
Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice ExperimentDominik Menges, Michela C Piatti, Aurelius Omlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2023
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate CancerAurelius Omlin, Richard Cathomas, Gunhild von Amsberg, et al.
JAMA Network Open|April 21, 2026
Prostate Cancer Incidence, Mortality, and Survival in SwitzerlandDominik Menges, Lea Wildisen, Thomas Scherer, et al.
Urologic Oncology|February 21, 2026
Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective studyEmily Rinderknecht, Gloria Bielstein, Richard Cathomas, et al.
Clinical Lung Cancer|December 21, 2016
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialOliver Gautschi, Sacha I Rothschild, Qiyu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2021
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or EnzalutamideJohann S de Bono, Mark T Fleming, Judy S Wang, et al.
Swiss Medical Weekly|September 8, 2021
Swiss germ-cell cancer consensus recommendationsJörg Beyer, Dominik Berthold, Peter-Karl Bode, et al.
European Urology|May 4, 2020
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 GuidelinesJ Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al.
Pageof 14